EP4447963A1 — Selective phd1 inhibitor compounds, compositions, and methods of use
Assigned to Akebia Therapeutics Inc · Expires 2024-10-23 · 2y expired
What this patent protects
The present invention provides, in part, compounds and methods for treating diseases mediated by PHD1 activity (e.g., ischemia reperfusion injury (including but not limited to stroke, myocardial infarction, and acute kidney injury) inflammatory bowel disease, cancer (including co…
USPTO Abstract
The present invention provides, in part, compounds and methods for treating diseases mediated by PHD1 activity (e.g., ischemia reperfusion injury (including but not limited to stroke, myocardial infarction, and acute kidney injury) inflammatory bowel disease, cancer (including colorectal cancer) and liver disease) comprising administering to a subject to a subject a compound of Formula (I), and sub-formulas thereof: [Formula (I)] or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.